Deltagen (United States)

Recent papers from Deltagen (United States)

1. Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating PeptidesInternational Journal of Molecular Sciences · 2026
2. An Analysis of PD1 Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13Neuro-Oncology Pediatrics · 2026
3. Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptides2025
4. Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White PaperClinical Pharmacology & Therapeutics · 2024
5. Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumorsCPT Pharmacometrics & Systems Pharmacology · 2022
6. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialLiver Cancer · 2022
7. Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 studyBritish Journal of Haematology · 2021
8. Pamiparib Monotherapy for Patients with Germline BRCA1/2 -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II StudyClinical Cancer Research · 2021
9. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetratorCPT Pharmacometrics & Systems Pharmacology · 2021
10. A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell LymphomaFuture Oncology · 2020
11. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaFuture Oncology · 2020
12. No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy SubjectsClinical and Translational Science · 2020
13. The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazardsPharmaceutical Statistics · 2019
14. Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell LymphomaHematological Oncology · 2019
15. RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular CarcinomaFuture Oncology · 2019
16. The C3a Anaphylatoxin Receptor Is a Key Mediator of Insulin Resistance and Functions by Modulating Adipose Tissue Macrophage Infiltration and ActivationDiabetes · 2009
17. Targeted Disruption of Peptide TransporterPept1Gene in Mice Significantly Reduces Dipeptide Absorption in IntestineMolecular Pharmaceutics · 2008
18. Cellular Recognition of Trimyristoylated Peptide or Enterobacterial Lipopolysaccharide via Both TLR2 and TLR4Journal of Biological Chemistry · 2007
19. Deficiency of Adiponectin Receptor 2 Reduces Diet-Induced Insulin Resistance but Promotes Type 2 DiabetesEndocrinology · 2006
20. The G s -Linked Receptor GPR3 Maintains Meiotic Arrest in Mammalian OocytesScience · 2004